Information Provided By:
Fly News Breaks for April 3, 2018
PTCT
Apr 3, 2018 | 16:19 EDT
Barclays analyst Gena Wang downgraded PTC Therapeutics to Underweight from Equal Weight while raising her price target for the shares to $26 from $24. The stock closed the trading day up 15c to $26.12. The analyst sees limited upside to 2018 revenue expectations and believes PTC's growth trajectory is fully priced in at current valuation levels.
News For PTCT From the Last 2 Days
PTCT
Mar 28, 2024 | 08:34 EDT
PTC Therapeutics submitted the sepiapterin MAA to the European Medicines Agency, or EMA. The MAA submission is for the treatment of pediatric and adult patients with Phenylketonuria, including the full spectrum of disease subtypes. Phenylketonuria, or PKU, is a rare, inherited metabolic disease, which affects the brain. The sepiapterin MAA includes the results of the phase 3 APHENITY trial in which sepiapterin had a statistically significant and clinically meaningful reduction in blood phenylalanine levels in pediatric and adult PKU patients. PTC expects to submit the sepiapterin NDA to the FDA no later than the third quarter of 2024. Submissions in 2024 are planned in a number of additional key countries where PTC has existing rare disease commercial infrastructure including Brazil and Japan.